drugset
drugset / Trial / NCT05234437

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

NCT05234437 ↗

Phase 2 Terminated 1 enrolled QBiotics Group Limited
NaSingle-groupOpen-labelTreatment

Summary

A phase IIb, multicentre, open label study to evaluate the effectiveness, safety, and tolerability of intratumoural tigilanol tiglate in adult participants with Stage IIIB to IV M1c melanoma

Timeline

Start
2022-03-09
Primary completion
2022-07-18
Completion
2022-07-18

Outcome

Outcome not reported

Stopped (Enrollment): “Insufficient Patient Recruitment Rates”

Drugs

EvaluationDrugModalityDoseRoute
Subject Tigilanol Tiglate Small molecule 3.6 mg/m2 Other

Indications

melanoma